The first patients to take part in the study have been recruited at Peterborough City Hospital, with the Rosie Hospital, Cambridge recently also starting recruitment.

The PEMP study aims to improve the understanding of the disease physiology of endometriosis, a condition that affects 1 in 10 women, yet has limited available treatments due to a lack of available data and disease models. Cyclana Bio will use human data and cells collected from both biopsies and menstrual fluid donated by participants in the study to build physiologically relevant in vitro 3D models of the disease. These models will help uncover the basic biology and support the identification and prioritisation of novel druggable targets for therapeutic development. The Company also aims to develop tools to better stratify patients based on clinical need, highlighting not just endometriosis but the differences in the disease.